| Year |
Citation |
Score |
| 2021 |
Xia Y, Ji X, Jang IS, Surka C, Hsu C, Wang K, Rolfe M, Bence N, Lu G. Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform. Communications Biology. 4: 834. PMID 34215850 DOI: 10.1038/s42003-021-02352-2 |
0.324 |
|
| 2019 |
Menden MP, Wang D, Mason MJ, Szalai B, Bulusu KC, Guan Y, Yu T, Kang J, Jeon M, Wolfinger R, Nguyen T, Zaslavskiy M, Jang IS, Ghazoui Z, et al. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nature Communications. 10: 2674. PMID 31209238 DOI: 10.1038/S41467-019-09799-2 |
0.498 |
|
| 2019 |
Lu G, Surka C, Lu C, Jang IS, Wang K, Rolfe M. Elucidating the Mechanism of Action of CC-90009, a Novel Cereblon E3 Ligase Modulator, in AML Via Genome-Wide CRISPR Screen Blood. 134: 405-405. DOI: 10.1182/Blood-2019-125492 |
0.348 |
|
| 2018 |
Lu G, Weng S, Matyskiela M, Zheng X, Fang W, Wood S, Surka C, Mizukoshi R, Lu CC, Mendy D, Jang IS, Wang K, Marella M, Couto S, Cathers B, et al. UBE2G1 governs the destruction of cereblon neomorphic substrates. Elife. 7. PMID 30234487 DOI: 10.7554/Elife.40958 |
0.302 |
|
| 2018 |
Xu C, Nikolova O, Basom R, Mitchell RM, Shaw R, Moser R, Park H, Gurley KE, Kao M, Green CL, Schaub FX, Diaz RL, Swan HA, Jang IS, Guinney J, et al. Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29599409 DOI: 10.1158/1078-0432.Ccr-17-1339 |
0.629 |
|
| 2015 |
Dienstmann R, Jang IS, Bot B, Friend S, Guinney J. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. Cancer Discovery. 5: 118-23. PMID 25656898 DOI: 10.1158/2159-8290.Cd-14-1118 |
0.467 |
|
| 2015 |
Jang IS, Dienstmann R, Margolin AA, Guinney J. Stepwise group sparse regression (SGSR): gene-set-based pharmacogenomic predictive models with stepwise selection of functional priors. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing. 32-43. PMID 25592566 |
0.659 |
|
| 2014 |
Moser R, Xu C, Kao M, Annis J, Lerma LA, Schaupp CM, Gurley KE, Jang IS, Biktasova A, Yarbrough WG, Margolin AA, Grandori C, Kemp CJ, Méndez E. Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4274-88. PMID 25125259 DOI: 10.1158/1078-0432.Ccr-13-2858 |
0.612 |
|
| 2014 |
Cermelli S, Jang IS, Bernard B, Grandori C. Synthetic lethal screens as a means to understand and treat MYC-driven cancers. Cold Spring Harbor Perspectives in Medicine. 4. PMID 24591535 DOI: 10.1101/Cshperspect.A014209 |
0.43 |
|
| 2014 |
Jang IS, Neto EC, Guinney J, Friend SH, Margolin AA. Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing. 63-74. PMID 24297534 |
0.633 |
|
| 2014 |
Neto EC, Jang IS, Friend SH, Margolin AA. The Stream algorithm: computationally efficient ridge-regression via Bayesian model averaging, and applications to pharmacogenomic prediction of cancer cell line sensitivity. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing. 27-38. PMID 24297531 |
0.58 |
|
| 2014 |
Ferte C, Chaibub Neto E, Commo F, Nikolova O, Jang iS, Gonen M, Lacroix L, Koubi-Pick V, Angevin E, Besse B, Ducreux M, Hollebecque A, Massard C, Margolin A, Friend SH, et al. Joint cell-line and patient modeling of drug sensitivity reveals novel molecular biomarkers for targeted and conventional chemotherapy. Journal of Clinical Oncology. 32: 2565-2565. DOI: 10.1200/Jco.2014.32.15_Suppl.2565 |
0.638 |
|
| 2014 |
Nikolova OH, Gönen M, Dienstmann R, Jang IS, Moser R, Cermelli S, Xu C, Mitchell RM, Mendez E, Grandori C, Kemp C, Friend S, Guinney J, Margolin A. Abstract 5323: Integrated computational cell-line modeling of drug sensitivity and high-throughput siRNA screening reveals novel molecular biomarkers for conventional chemotherapy Cancer Research. 74: 5323-5323. DOI: 10.1158/1538-7445.Am2014-5323 |
0.677 |
|
| 2013 |
Jang IS, Margolin A, Califano A. hARACNe: improving the accuracy of regulatory model reverse engineering via higher-order data processing inequality tests. Interface Focus. 3: 20130011. PMID 24511376 DOI: 10.1098/Rsfs.2013.0011 |
0.636 |
|
| 2013 |
Bilal E, Dutkowski J, Guinney J, Jang IS, Logsdon BA, Pandey G, Sauerwine BA, Shimoni Y, Moen Vollan HK, Mecham BH, Rueda OM, Tost J, Curtis C, Alvarez MJ, Kristensen VN, et al. Improving breast cancer survival analysis through competition-based multidimensional modeling. Plos Computational Biology. 9: e1003047. PMID 23671412 DOI: 10.1371/Journal.Pcbi.1003047 |
0.656 |
|
| 2013 |
Ferté C, Neto EC, Sun C, Noecker C, Commo F, Nikolova O, Jang IS, Gonen M, Besse B, André F, Angevin E, Lacroix L, Mazoyer C, Hollebecque A, Massard C, et al. Abstract A130: Joint cell-line (CCLE, Sanger) and patient (TCGA) modeling of drug sensitivity reveals novel molecular biomarkers for targeted therapy and conventional chemotherapy. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A130 |
0.677 |
|
| 2013 |
Moser R, Xu C, Kao M, Jang IS, Gurley K, Margolin A, Grandori C, Mendez E, Kemp C. Abstract PR05: Construction of synthetic lethal networks for p53 tumor suppressor pathways identifies candidate therapeutic targets for metastatic, chemotherapy resistant HNSCC Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Pr05 |
0.611 |
|
| 2013 |
Toyoshima M, Jang IS, Cermelli S, Bernard B, Grandori C. Abstract IA11: Identification of therapeutic targets for MYC-driven cancers by functional genomics Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Ia11 |
0.476 |
|
| 2012 |
Margolin AA, Jang IS, Friend S. Abstract IA15: Predicting drug sensitivity from cancer cell lines Cancer Research. 72. DOI: 10.1158/1538-7445.Csb12-Ia15 |
0.678 |
|
| Show low-probability matches. |